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S U M M A R Y
Objectives: In the winter of 2013, people were facing the risk of human-to-human transmission of the re-
emerging inﬂuenza A(H7N9) virus. We report herein information on the clinical features of two patients
from the same family infected with this virus, the genomic sequences of the viruses harbored, and
antiviral drug sensitivity.
Methods: Clinical and epidemiological data of two patients from the same family were collected and
analyzed. Sequencing was done for the viruses isolated from these two patients and one
epidemiologically related chicken, and the sequences of the eight gene segments of the viruses were
analyzed phylogenetically. The sensitivity of the viruses to antiviral drug treatment was determined by
neuraminidase inhibitor susceptibility test.
Results: The two patients from one family cluster shared the same symptoms but had different
outcomes, and had a strong epidemiological link. Three strains, two from these two patients and one
from the chicken, were isolated. Genome sequencing and analyses of phylogenetic trees demonstrated
that the two viruses were almost identical. We noted the presence of the PB2 E627K amino acid
substitution that was not present in isolates from the ﬁrst wave, as well as two new mutations in the NA
gene and six in the PB2 gene. Drug sensitivity testing showed that the new isolates were resistant to
oseltamivir but sensitive to peramivir.
Conclusions: The two patients from one family cluster were probable human-to-human transmission
cases. The new isolates were sensitive to peramivir but showed reduced sensitivity to oseltamivir.
 2014 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-SA license (http://creativecommons.org/licenses/by-
nc-sa/3.0/).
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jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j id1. Introduction
As of July 14, 2014, a total of 451 cases of avian origin inﬂuenza
A(H7N9) infection had been reported to the World Health
Organization (WHO).1 The ﬁrst epidemic wave of inﬂuenza
A(H7N9) in China occurred from February to May of 2013, and
the second epidemic wave was from October 2013 to April* Corresponding author.
E-mail address: ljli@zju.edu.cn (L.J. Li).
http://dx.doi.org/10.1016/j.ijid.2014.10.029
1201-9712/ 2014 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-sa/3.0/).2014. The virus seems not to cause diseases in poultry and thus
they could serve as a reservoir of infection that may lead to
frequent sporadic human infections.
In experiments in ferrets, the H7N9 virus replicated well in the
upper and lower respiratory tract and was efﬁciently transmitted
by direct contact following intranasal inoculation.2 This led to the
conclusion that under appropriate conditions, human-to-human
transmission of the H7N9 virus may be possible.
We report a family cluster of two patients infected with the re-
emerging virus in the winter of 2013. Information on variation in
the viral genome, antiviral drug sensitivity, and the clinicalciety for Infectious Diseases. This is an open access article under the CC BY-NC-SA
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establish whether the family cluster of cases occurred as a result of
possible human-to-human transmission and to determine the
effects of neuraminidase inhibitors on these new isolated viruses.
2. Methods
2.1. Data and sample collection
Clinical features including demographic characteristics, labo-
ratory abnormalities, viral kinetics, treatment, clinical outcome,
and epidemiological data were obtained from the family cluster of
two laboratory-conﬁrmed H7N9 virus-infected patients on De-
cember 16, 2013. A standardized form, described previously by
Gao et al.3 and Li et al.,4 was used to collect the data.
All household members who had been in close contact with the
two patients were placed under medical observation until 7 days
after the patients had been isolated in the hospital. Paired serum
samples (the interval between the two samples was at least
3 weeks) were collected and investigated to ascertain potential
human-to-human transmission as well as asymptomatic and
subclinical infections.
The ﬁrst sputum specimens were obtained when the patients
were hospitalized and had not yet initiated antiviral therapy. Feces
of 33 chickens were obtained from epidemiologically linked wet
markets (all from Anji County, Zhejiang). The research ethics board
of the First Afﬁliated Hospital, Zhejiang University approved the
study design.
2.2. H7N9 laboratory assays
The ﬁrst sputum specimens of the patients and the excreta
specimens of the chickens, delivered in viral transport medium,
were tested by real-time reverse-transcriptase PCR (RT-PCR) assay
to conﬁrm H7N9 virus infection. RNA was extracted from
specimens with the RNeasy Mini Kit (Qiagen, Valencia, CA, USA)
using the manufacturer’s protocol and were tested by real-time RT-
PCR with H7N9-speciﬁc primers and probes, as described
previously by Gao et al.3 and Li et al.4 The speciﬁc sequences
have been published on the WHO website at http://www.who.int/
inﬂuenza/gisrs_laboratory/a_h7n9/en/.
Samples were diluted with equal amounts of the virus growth
liquid and ﬁltered centrifugally. The ﬁltrate liquid was cultured in
Madin–Darby canine kidney (MDCK) cells for virus isolation,
including one to three blind passages, as described previously.3
When most of the cells had positive cytopathic changes, the
supernatant of the culture solution was harvested and virus
infection was conﬁrmed by RT-PCR. Virus handling was conducted
in an enhanced biosafety level 3 containment facility, in
accordance with institutional guidelines.
Genome sequencing was done for two human isolates and one
chicken isolate. All eight gene segments of the patient and chicken
isolates together with the ﬁrst wave isolates from the same county
were deposited in GenBank; these sequences along with the other
virus sequence data available in GenBank were characterized and
analyzed phylogenetically. The sequences were analyzed using
BioEdit version 7.0.9.0 DNA analysis software. Phylogenetic trees
were constructed using MEGA5 software version 5.05, applying the
neighbor-joining method with bootstrap analysis (1000 repli-
cates).5 The sequence data obtained in this study have been
deposited in GenBank under accession numbers KM879319–
KM879326 (chicken isolate).
Drug sensitivities of oseltamivir (Roche Diagnostics GmbH,
Mannheim, Germany) and peramivir (Nanxin Pharmaceuticals,
Guangzhou, China) were assessed by neuraminidase inhibitor
(NAI) susceptibility test using the method described by Gubarevaet al.6 The IC50 values (drug concentrations required to inhibit NA
activity by 50%) were used to characterize NAI susceptibility. To
interpret the NAI susceptibility, the WHO criteria based on the fold
change of IC50 values compared with reference IC50 values were
applied.7 For inﬂuenza A viruses, normal inhibition was deﬁned as
a <10-fold increase, reduced as a 10–100-fold increase, and highly
reduced as a >100-fold increase.
3. Results
3.1. Epidemiology, clinical features, and laboratory abnormalities
The index patient was a man aged 57 years with a history of
hypertension for more than 10 years. He lived in a semi-urban area
of Anji County in Zhejiang Province. There was a wet market where
several kinds of live poultry were sold located about 1000 m from
his district of residence. He was responsible for purchasing food for
the whole family every day. He returned to his hometown in a rural
area and cleaned the chicken coop on November 16, 2013; a fever
developed on November 21, following an incubation period of
5 days.
The second patient was a 31-year-old male, the son-in-law of
the index patient. He was a businessman and lived in the same
county as the index patient, but not in the same district of
residence, and came into occasional contact with the index patient.
He fell sick on November 30. The second patient denied a history of
exposure to poultry or any animal and had not been to a wet
market during the 2 weeks prior to the onset of illness. He had
come into close contact with the index patient during the period
November 20 to November 26, including being in the same room,
talking with the index patient, and providing unprotected bedside
care to him; the time density of contact was from 0.3 to 18 h per
day. During this exposure, the index patient had a continuous
productive cough. The incubation period for the secondary case
ranged from 4 to 10 days. Epidemiological data and detailed
exposure and timeline information are available in the Supple-
mentary Material (Figure S1 and Tables S1 and S2).
The youngest daughter of the index patient – the wife of the
second patient, who was in her ﬁrst trimester of pregnancy –
provided unprotected care to the index patient and the second
patient, one after the other, until the second patient was isolated in
a negative-pressure ward. She had the same density of contact
time with the index patient as the second patient and did not have
any symptoms. Hemagglutination inhibition antibodies against
A(H7N9) virus were detected in paired serum samples from this
daughter (three serum samples were collected because we needed
to calculate the exposure time again when the second patient
developed symptoms); the remaining household members were
negative.
The abnormal clinical and laboratory ﬁndings are given in the
Supplementary Material (Table S3). Both patients had a fever,
productive cough, and shortness of breath, and the second patient
had diarrhea. The two patients also had elevated levels of creatine
kinase, lactate dehydrogenase, and C-reactive protein. Both had
lymphopenia. We noted that the pneumonia began in one segment
of the left lung and spread to other segments and even the
contralateral lung in both patients (Supplementary Material,
Figure S2). The condition of the index patient deteriorated further
until he became dependent on extracorporeal membrane oxygen-
ation (ECMO). Oseltamivir was initiated 4 days after the onset of
illness and at that time this patient already had involvement of
both lungs. He became negative for the virus after 15 days of
therapy.
The second patient received oseltamivir therapy once at an
outpatient clinic. When he was admitted, he received peramivir in
order to prevent the delayed viral clearance observed in the index
H.N. Gao et al. / International Journal of Infectious Diseases 29 (2014) 254–258256patient. At that time, the second patient had pneumonia in two
segments of the left lung. His symptoms were controlled rapidly.
Five days later he became negative for the virus and 11 days later
was discharged having made a full recovery. There was no evidence
of any bacterial co-infection in either patient, however the index
patient had a continuous secondary infection during the hospitali-
zation (see Supplementary Material, Table S4).
3.2. Laboratory investigations
Strains isolated from these two patients were named A/
Zhejiang/DTID-ZJU17/2013 (ZJU17) and A/Zhejiang/DTID-ZJU18/
2013 (ZJU18). Five out of 33 chickens tested positive for the H7N9
virus. We selected one strain, named A/chicken/Zhejiang/DTID-
ZJU06/2013 (chicken/ZJU06), for analysis together with the strains
isolated from humans. The sequences of all eight genes of ZJU17
and ZJU18 were almost identical (similarity ranging from 99.8% to
100%), but were slightly different from the sequences from the
chicken (similarity ranging from 94.4% to 99.9%) (see Supplemen-
tary Material, Table S5). Further phylogenetic analysis showed
that the eight genes of ZJU17 and ZJU18 belonged to the same clade
(Supplementary Material, Figure S3).
Analysis of the critical amino acids related to mammalian
adaptation and drug resistance showed that both strains were
the same as strains ZJU01 and ZJU10 that were isolated during
the ﬁrst wave in 2013 in the same county. Analysis of the H7
receptor-binding site showed a G186 V substitution (H3
numbering) and a G226L substitution (H3 numbering) in both
the human and chicken isolates, which have been associated
with an increasing binding afﬁnity for the a(2–6)-linked sialic
acid receptor. In NA, no R289K (N9 numbering) substitution
associated with neuraminidase inhibitors was found in ZJU17
and ZJU18. However, we noted an E627K substitution in the PB2
protein in both ZJU17 and ZJU18, but no D701N substitution,
which has been associated with enhanced transmission in
guinea pigs, as was reported in ZJU01 during the ﬁrst wave. Two
amino acid mutations (75 and 335) in the NA protein and six
amino acid mutations (191, 511, 535, 570, 647, and 702) in PB2
were noted, and these mutations have not been found in
previously reported H7N9 viruses (Table 1).Table 1
Mutation analysis of critical and apparent amino acid residues of inﬂuenza A(H7N9) v
Segment Location A/Zhejiang/
DTID-ZJU17/
2013
A/Zhejiang/
DTID-ZJU18/
2013
A/chicken/
Zhejiang/
DTID-ZJU06/
2013
A/Zhejiang
DTID-ZJU01
2013
HA 186 (H3
numbering)
V V V V 
226 (H3
numbering)
L L L L 
NA
289 (N9
numbering)
R R R R 
75 K K K R 
335 E E E D 
PB2
627 K K E E 
701 D D D N 
191 E E E K 
511 I I I V 
535 L L L M 
570 I I I M 
647 V V I I 
702 R R K K 
M
31 N N N 
NS1 42 S S S Due to the delayed viral clearance in the index patient, we
performed drug sensitivity testing of oseltamivir and peramivir for
these two new isolates and compared results with those of
15 isolates from the ﬁrst wave in the same district. For the two new
isolates, the IC50 values of oseltamivir were 23.94 and 16.12 nmol/l
(mean value 20.03 nmol/l). For the 15 isolates from the ﬁrst wave,
the mean IC50 value of oseltamivir was 1.14  0.58 nmol/l. A more
than 10-fold increase in IC50 value was observed in the two new
isolates when compared with the 15 isolates from the ﬁrst wave. With
regard to peramivir, there was no difference in the IC50 values
between the new isolates and the 15 isolates from the ﬁrst wave: IC50
values of 0.64 and 0.92 nmol/l (mean value 0.78 nmol/l) for the new
isolates and mean value 0.63  0.26 nmol/l for the 15 isolates from
the ﬁrst wave (Figure 1).
4. Discussion
A family cluster of two patients with H7N9 virus infection
emerged in the winter of 2013. Genome sequencing showed
identical sequences of the strains isolated from these two cases. No
mutation related to the known drug resistance sites was found.
Drug sensitivity testing showed that these new isolates had more
than 10-fold decreased drug sensitivity to oseltamivir when
compared with strains isolated in the ﬁrst wave. These ﬁndings
show that limited human-to-human transmission of the virus
probably occurred in the family cluster and indicate the reduced
sensitivity of the new isolates to oseltamivir, which may be an
early warning signal of resistance to oseltamivir for this virus.
The index patient may have transmitted the virus to his son-in-
law through close unprotected contact. First, they both had
conﬁrmed H7N9 infections. Second, there was a strong epidemio-
logical link between them, and the sequences of the viruses
isolated from these two patients were highly identical to each
other, including the mutation sites. Sequence analysis showed an
E627K mutation in the PB2 protein that was not reported in the
same county during the ﬁrst wave. The PB2 E627K mutation
appears to be of key importance to the human adaptation and
increased virulence of the H7N7 inﬂuenza virus in humans8 and
H7N9 virus in mice.9 Two viral strains isolated from another family
cluster of cases of H7N9 virus infection reported in Jiangsuirus isolates in Anji County, 2013
/
/
A/Zhejiang/
DTID-ZJU10/
2013
A/chicken/
Zhejiang/
DTID-ZJU01/
2013
Function
V V G!V increases binding afﬁnity for
a(2–6)-linked sialic acid receptor
L L Q!L increases binding afﬁnity for
a(2–6)-linked sialic acid receptor
R R R!K reduces susceptibility to oseltamivir
R R These mutations have not been found in
previously reported H7N9 virusesD D
E/K E E!K enhanced transmission
D D D!N enhanced transmission in guinea pigs
K K These mutations have not been found in
previously reported H7N9 virusesV V
M M
M M
I I
K K
S!N causes resistance to adamantanes
P!S
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Figure 1. Comparison of drug susceptibility between oseltamivir and peramivir for different viral strains from the same district. (A) A more than 10-fold increase in IC50 value
was observed for the two new isolates when compared with the 15 isolates from the ﬁrst wave. The IC50 value of oseltamivir was 23.94 and 16.12 nmol/l for ZJU17 and ZJU18,
respectively (mean value 20.03 nmol/l), and a mean 1.14  0.58 nmol/l for the 15 isolates from the ﬁrst wave. (B) There was no difference in IC50 values for peramivir between the
new isolates and the 15 isolates from the ﬁrst wave: the IC50 values were 0.64 and 0.92 nmol/l for the new isolates (mean value 0.78 nmol/l) and a mean 0.76  0.37 nmol/l for the
15 isolates from the ﬁrst wave.
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PB2 E627K mutation compared with the ﬁrst wave in the same
district may be further evidence that the family cluster of two
patients involved probable human-to-human transmission. We
noted another six amino acid mutations in the PB2 protein. We
cannot rule out the possibility that these particular mutations also
increased the capacity of the virus for human adaptability.
NAIs are the ﬁrst-line therapeutic options against H7N9 virus.
Previous research has identiﬁed three oseltamivir-resistant
strains: A/shanghai/1/2013,3 A/Taiwan/S02076/2013, and A/
Taiwan/T02081/2013. They all had the R294K substitution, which
reduces the effectiveness of oseltamivir by over 100 000-fold using
protein- and virus-based assays.11 However, crystal structure
analysis of the neuraminidase N9 also showed that the R294K
substitution would interfere with its binding to sialic acid and
reduce viral ﬁtness. This explains why oseltamivir-resistant
viruses are not dominant human-infecting viruses. Another
explanation is that the virus exists in the human body with a
‘quasispecies’ formation, and oseltamivir resistance is from the
selective pressure during oseltamivir therapy.
In real-life clinical practice, we found delayed clearance of the
virus after oseltamivir therapy. In addition to drug resistance,
another possible explanation is the delayed initiation of antiviral
treatment. The analysis of 111 cases of inﬂuenza A(H7N9) virus
infection showed antiviral drug therapy was initiated at a median
of 7 days after the onset of illness.12 Glucocorticoid usage is
another possibility.13 However, in our drug sensitivity testing, we
noted the reduced sensitivity of the virus to oseltamivir, which was
identical to the phenomenon of delayed viral clearance during
oseltamivir therapy. Selective pressure from antiviral therapy
cannot explain this phenomenon, as we isolated the virus from the
sputum specimens collected before antiviral therapy. Also, we
found two amino acid mutations in the NA protein of the new
isolates when comparing them with ZJU01 isolated during the ﬁrst
wave in the same district, which was sensitive to oseltamivir on in
vitro testing. We cannot rule out the possibility that these
mutations are related to the drug resistance of the H7N9 virus.
Further work is needed to investigate the function of these two
mutations. We cannot ignore quasispecies formation of the virus
either. For the sensitivity limit, using routine sequencing methods,
we could not identify the existing resistance site. Of note, because
the number of virus strains studied here was small, these may not
represent the features of all re-emerging A(H7N9).
Our study has several limitations. First, we cannot completely
rule out environmental transmission for these two patientsbecause we did not analyze environmental samples. Secondly,
we cannot explain why the symptoms and outcomes of this family
cluster of two patients were so different, although we think that
these two patients were infected by the same virus strain. Besides
the virulence of the virus, the potential bacterial co-infection and
the different antiviral drug treatment regimens used in these two
patients may have played an important role. Also, we cannot
exclude the possibility that during spread among humans, the
virulence of the virus is decreased. Thirdly, we cannot explain why
with the same exposure density, the daughter of the index patient
did not fall sick. Finally, we do not know the signiﬁcance of the two
amino acid mutations in the NA protein and the six amino acid
mutations in the PB2 protein. Further crystal structure and
function characterization is needed.
In conclusion, although current data do not indicate that
A(H7N9) is readily transmissible among humans, we should
always be alert to the human-to-human property of this virus.
Close monitoring of the variation among more A(H7N9) viruses
and the antiviral drug sensitivity are required.
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